1. Resistance to secondary infection
Induction of Trained Innate Immunity
Low dose
Β-glucan
Dectin-1
RAF-1
Epigenetic modification
of histones
Increased
transcription A M
Resistance to secondary infection
Monocyte
Cellular activation
Cytokine production
Vaccine Adjuvants
Biomarkers of Disease
Serum
MBL
High
Low
Susceptibility to Infection
Association with autoimmunity
Mincle
Antigen coupled Mab
TDB
DEC205
Vaccine mediated
Protection
CLEC9A
Tfh
Antigen
Presentation
Th1
Th17 a b c
Induction of Anti-Tumour Response
LOX1
CLR Antagonists
Atherosclerotic plaque formation
Ox-LDL
RBC
Endothelium
LOX1 inhibitor
Lumen Blood Vessel
CD23
Anti-fungal Drug Improvements
NFAT
NOS &
Fungal killing
JNK1 p
Dectin-1
C. albicans
Fcer2a
JNK Inhibitors
Β-glucan
Treatment
Tumour
Dectin-1
PMN-MDSC
M-MDSC
Apoptosis
Improved
Anti-tumour
response
Antigen
APC
Presentation
CD4
CD8 d e f
Brown et al Box 2 Schematic